Long-term survival following photodynamic therapy for malignant glioma depending on MGMT statusстатья

Статья опубликована в высокорейтинговом журнале

Информация о цитировании статьи получена из Web of Science
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 28 октября 2020 г.

Работа с статьей


[1] Long-term survival following photodynamic therapy for malignant glioma depending on mgmt status / А. Ю. Рында, В. Е. Олюшин, Д. М. Ростовцев, Ю. М. Забродская // Annals of Oncology. — 2020. — Vol. 31, no. Suppl. 4. — P. 377P. BackgroundThe aim of the study was to increase the survival rate and duration of the relapse-free period in patients with malignant brain gliomas by using photodynamic therapy as part of complex treatment.MethodsThe study included patients with glial brain tumours of supratentorial localization with a high degree of malignancy (Grade IV - glioblastoma), undergoing treatment at the Russian Neurosurgical Institute named after Prof. A.L. Polenova. The study group consisted of 50 patients and there were 50 patients in the control group. Patients in the study group were injected intravenously 1.5 hours before the operation with a photosensitizer of the chlorine E6 group (2nd generation). After resection of the tumour, a photodynamic therapy (PDT) session was performed using a Latus-2.5 laser as a radiation source. The average dose was 180 J / cm2. In the postoperative period, patients in both groups received adjuvant therapy (chemotherapy and radiation therapy). Long-term results (interrecurrence period, overall survival) were evaluated depending on the results of immunohistochemical studies (the presence of IDH mutation and MGMT).ResultsThe median survival for patients with Grade IV gliomas (MGMT +) using PDT was 23.3 ± 4.1 months; in the control group (without PDT) the median survival was 16.5 ± 3.3 months (P = 0.0002). The median survival for patients with Grade IV gliomas (MGMT-) using PDT was 18.2 ± 3.5 months; in the control group (without PDT) this was 11.2 ± 2.4 months (P = 0.0001). The median duration of the inter-relapse period for patients with Grade IV gliomas (MGMT +) was 13.5 ± 2.3 months in the study group and 9.1 ± 1.4 months in the control group (P = 0.0003). The median duration of the inter-relapse period for patients with Grade IV gliomas (MGMT-) was 10.1 ± 2.2 months in the study group and 7.0 ± 1.1 months in the control group (P = 0.0001).ConclusionsPhotodynamic therapy increases the median of the inter-relapse period and life expectancy in patients with malignant gliomas. In patients expressing MGMT, the magnitude of the inter-relapse period and life expectancy was significantly higher in the group receiving PDT. [ DOI ]

Публикация в формате сохранить в файл сохранить в файл сохранить в файл сохранить в файл сохранить в файл сохранить в файл скрыть